{
  "pathway": "Pharmacy First - Shingles (adults 18 years and over)",
  "metadata": {
    "version": "1.0",
    "lastUpdated": "2025-02-15",
    "sources": [
      "https://clinicalpathways.uk/pharmacy/shingles/",
      "https://cks.nice.org.uk/topics/shingles/",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-2a.-Shingles-aciclovir-patient-group-direction-Pharmacy-First.pdf",
      "https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN01010-2b.-Shingles-valaciclovir-patient-group-direction-Pharmacy-First.pdf"
    ],
    "niceGuideline": "NICE CKS Shingles"
  },
  "notes": [
    "Exclude pregnant individuals and anyone under 18 years - outside of the Pharmacy First specification.",
    "Document rash onset, dermatomal distribution, vesicle status, pain score and risk factors in the consultation record and include the Pharmacy First notification to the GP within 1 working day.",
    "Share the British Association of Dermatologists shingles leaflet (self-care, hygiene, covering rash, avoiding contact with non-immune pregnant people, immunosuppressed individuals and babies <1 month).",
    "For immunosuppressed patients notify the GP (or urgent GP email) the same day after supply and advise attendance at A&E/999 if systemic symptoms or rapidly spreading rash develop.",
    "Encourage adequate analgesia (paracetamol +/- ibuprofen or OTC co-codamol) and signpost eligible adults to shingles vaccination once fully recovered."
  ],
  "decisionTree": {
    "id": "complication_screen",
    "type": "decision",
    "title": "Consider the risk of deterioration or serious illness",
    "question": "Does the patient have complications or meet NHS Pharmacy First high-risk criteria?",
    "details": {
      "urgentComplications": [
        "Ophthalmic involvement (eye pain, visual change, periorbital swelling, vesicles on the nose/Hutchinson sign).",
        "Neurological symptoms: meningism, encephalitis signs, confusion, altered mental state, acute headache, facial palsy/Ramsay Hunt, limb weakness or unsteady gait.",
        "Disseminated or multidermatomal shingles, rapidly spreading rash or signs of bacterial superinfection.",
        "Severe systemic illness, NEWS2 trigger, sepsis features or immunosuppressed patient with red flags."
      ],
      "highRiskGroups": [
        "Pregnant individuals (Pharmacy First exclusion).",
        "Adults with significant cardiac, respiratory, renal or hepatic disease.",
        "People on high-dose systemic corticosteroids, chemotherapy, radiotherapy, biological or JAK inhibitor therapy.",
        "Solid organ or stem-cell transplant recipients, advanced HIV (CD4 <200) or other severe immunodeficiency."
      ],
      "escalation": [
        "Calculate NEWS2 before signposting to A&E or calling 999 for life-threatening deterioration.",
        "Escalate ophthalmic or neurological presentations for same-day medical assessment even if vitals stable."
      ]
    },
    "yes": {
      "id": "urgent_referral",
      "type": "action",
      "title": "Urgent medical review required",
      "actions": [
        "Consider NEWS2 and arrange 999/A&E transfer for life-threatening illness.",
        "Refer immediately to general practice, urgent care or ophthalmology/neurology when complications suspected.",
        "Provide safety-netting and document reason for escalation."
      ],
      "safetyNet": true
    },
    "no": {
      "id": "typical_features",
      "type": "decision",
      "title": "Diagnose shingles on clinical grounds",
      "question": "Does the patient follow the typical progression of shingles clinical features?",
      "details": {
        "typicalFeatures": [
          "Prodromal dermatomal pain, tingling or burning followed by unilateral vesicular eruption on an erythematous base.",
          "Grouped vesicles limited to one dermatome (thoracic, cranial) that crust within 7-10 days.",
          "Possible mild fever, headache or malaise but otherwise systemically well."
        ],
        "considerAlternatives": [
          "Bacterial cellulitis/impetigo, eczema herpeticum, contact dermatitis, insect bites, herpes simplex."
        ],
        "documentation": [
          "Record dermatomes involved, stage of lesions and pain score using VAS or British Pain Society scale."
        ]
      },
      "yes": {
        "id": "gateway_72h",
        "type": "decision",
        "title": "Gateway point",
        "question": "Has the patient presented within 72 hours of rash onset?",
        "details": {
          "timingNotes": [
            "Antivirals provide greatest benefit when started within 72 hours of rash onset.",
            "Use the first appearance of vesicles or neuropathic pain if the exact time of eruption is unclear.",
            "Document onset date/time and dermatomes when submitting the Pharmacy First notification."
          ]
        },
        "yes": {
          "id": "criteria_within_72h",
          "type": "decision",
          "question": "Does the patient meet ANY of the Pharmacy First criteria (≤72 hours)?",
          "details": {
            "criteriaWithin72h": [
              "Immunosuppressed (chemotherapy, radiotherapy, high-dose systemic steroids ≥40 mg prednisolone daily for ≥1 week, biologics, transplant medicines, advanced HIV).",
              "Non-truncal involvement (cervical, cranial, limb or perineal shingles).",
              "Moderate or severe pain using a validated pain scale.",
              "Moderate or severe rash defined as confluent lesions.",
              "Age over 50 years."
            ]
          },
          "yes": {
            "id": "antiviral_supply_72h",
            "type": "treatment",
            "title": "Offer antiviral via PGD (≤72 hours)",
            "drug": "Aciclovir (first line) or Valaciclovir (if aciclovir unsuitable)",
            "durationDays": 7,
            "dose": {
              "Aciclovir first line": "800 mg orally five times daily (every 4 hours while awake). Start immediately and complete 7 days.",
              "Valaciclovir (if aciclovir contraindicated/unavailable, immunosuppressed or adherence risk)": "1 g orally three times daily for 7 days."
            },
            "formulations": [
              "Aciclovir 800 mg tablets (preferred) or 400 mg/200 mg tablets if 800 mg unavailable (swallow whole or disperse in ≥50 mL water).",
              "Valaciclovir 500 mg tablets (swallow whole with water)."
            ],
            "route": "Oral administration during waking hours.",
            "legalCategory": "POM supplied under PGD",
            "plus": [
              "Provide British Association of Dermatologists shingles leaflet and reinforce infection prevention (cover lesions, avoid sharing towels, hand hygiene, avoid contact with pregnant/non-immune/immunosuppressed contacts).",
              "Optimise analgesia: paracetamol +/- ibuprofen or OTC co-codamol; refer to GP if pain uncontrolled.",
              "Discuss shingles vaccination eligibility once recovered (at least 7 days after lesions crust)."
            ],
            "followUp": "If symptoms worsen rapidly, the rash spreads, or there is no improvement after completing 7 days, seek urgent medical review/A&E. Notify GP the same day for immunosuppressed patients and document Pharmacy First supply.",
            "safetyNet": true,
            "referralIfWorsen": true
          },
          "no": {
            "id": "no_treatment_criteria_72h",
            "type": "action",
            "title": "Patient does not meet ≤72 hour treatment criteria",
            "actions": [
              "Share self-care advice, analgesia plan and safety-netting.",
              "Explain that antivirals are not indicated without PGD criteria and ensure the patient knows when/how to seek help if the rash worsens."
            ],
            "safetyNet": true
          }
        },
        "no": {
          "id": "window_within_week",
          "type": "decision",
          "question": "Does the patient have shingles up to one week (7 days) after rash onset?",
          "details": {
            "timingNotes": [
              "Late presentations (>72 hours) may still benefit from antivirals if new vesicles continue or high-risk features present.",
              "If rash onset >7 days ago, antivirals are outside PGD scope unless directed by a prescriber."
            ]
          },
          "yes": {
            "id": "criteria_within_week",
            "type": "decision",
            "question": "Does the patient meet ANY of the Pharmacy First criteria (within 7 days)?",
            "details": {
              "criteriaWithin7d": [
                "Immunosuppressed (see criteria above).",
                "Continued vesicle formation.",
                "Severe pain despite analgesia.",
                "High risk of severe shingles (e.g. severe atopic dermatitis/eczema).",
                "All patients aged 70 years and over."
              ]
            },
            "yes": {
              "id": "antiviral_supply_within_week",
              "type": "treatment",
              "title": "Offer antiviral via PGD (≤7 days with risk factors)",
              "drug": "Aciclovir (first line) or Valaciclovir (if aciclovir unsuitable)",
              "durationDays": 7,
              "dose": {
                "Aciclovir first line": "800 mg orally five times daily (every 4 hours while awake). Start immediately and complete 7 days.",
                "Valaciclovir (if aciclovir contraindicated/unavailable, immunosuppressed or adherence risk)": "1 g orally three times daily for 7 days."
              },
              "formulations": [
                "Aciclovir 800 mg tablets (preferred) or 400 mg/200 mg tablets if 800 mg unavailable (swallow whole or disperse in ≥50 mL water).",
                "Valaciclovir 500 mg tablets (swallow whole with water)."
              ],
              "route": "Oral administration during waking hours.",
              "legalCategory": "POM supplied under PGD",
              "plus": [
                "Provide British Association of Dermatologists shingles leaflet and reinforce infection prevention (cover lesions, avoid sharing towels, hand hygiene, avoid contact with pregnant/non-immune/immunosuppressed contacts).",
                "Optimise analgesia: paracetamol +/- ibuprofen or OTC co-codamol; refer to GP if pain uncontrolled.",
                "Discuss shingles vaccination eligibility once recovered (at least 7 days after lesions crust)."
              ],
              "followUp": "If symptoms worsen rapidly, the rash spreads, or there is no improvement after completing 7 days, seek urgent medical review/A&E. Notify GP the same day for immunosuppressed patients and document Pharmacy First supply.",
              "safetyNet": true,
              "referralIfWorsen": true
            },
            "no": {
              "id": "no_treatment_criteria_week",
              "type": "action",
              "title": "Patient does not meet ≥72 hour treatment criteria",
              "actions": [
                "Explain that antivirals are outside PGD scope without continued vesicles, severe pain or other risk factors.",
                "Provide self-care support, analgesia guidance and red flag advice (seek help if systemic symptoms or rash spreads)."
              ],
              "safetyNet": true
            }
          },
          "no": {
            "id": "no_treatment_over_week",
            "type": "action",
            "title": "Rash onset >7 days",
            "actions": [
              "Patient does not meet treatment criteria - share self-care and safety-netting advice.",
              "Refer to GP if pain, rash or complications persist beyond 7 days."
            ],
            "safetyNet": true
          }
        }
      },
      "no": {
        "id": "alternative_diagnosis",
        "type": "action",
        "title": "Shingles less likely",
        "actions": [
          "Consider alternative diagnoses (impetigo, cellulitis, eczema herpeticum, HSV, contact dermatitis).",
          "Arrange onward referral or treatment according to the suspected condition and continue safety-netting."
        ],
        "safetyNet": true
      }
    }
  }
}
